-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised azacitidine,
decitabine+cedazuridine and midostaurin for patients with acute myeloid
leukaemia (AML).

AML and listing dates

AML is a type of cancer that affects the blood and bone marrow.

Listing dates:

-   azacitidine injection – 1 February 2011
-   midostaurin – 1 December 2018
-   decitabine+cedazuridine – 1 October 2022
-   azacitidine tablet – 1 September 2023

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements:

-   for azacitidine and midostaurin to the PBS Complex Drugs Programs
    team and choose the option relevant to the condition treated
-   for decitabine+cedazuridine to PBS authority approvals

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
websites.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
